Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ivar Roots

Showing results (21-30 of 97) with videos related to

Pageof 10
Sort By:
Pharmacogenetics|October 3, 2002
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteersJulia Kirchheiner, Ingolf Meineke, Gunnar Müller, et al.
Clinical Pharmacokinetics|December 24, 2005
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevanceJulia Kirchheiner, Ivar Roots, Mark Goldammer, et al.
Personalized Medicine|May 26, 2018
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsJulia Kirchheiner, Martina Tsahuridu, Wafaa Jabrane, et al.
Pharmacogenetics|December 4, 2003
Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activityJulia Kirchheiner, Johanna Sasse, Ingolf Meineke, et al.
Clinical Chemistry|January 24, 2002
Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCRIsabella Nowakowski-Gashaw, Przemyslaw M Mrozikiewicz, Ivar Roots, et al.
Pharmacogenetics|October 3, 2002
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosusPetra Zschieschang, Falk Hiepe, Erika Gromnica-Ihle, et al.
Biochemical and Biophysical Research Communications|September 13, 2005
Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patternsDieter Schwarz, Pyotr Kisselev, Alexey Chernogolov, et al.
Analytical Biochemistry|October 7, 2004
Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probesFarhad Arjomand-Nahad, Konstanze Diefenbach, Olfert Landt, et al.
Drug Metabolism Reviews|September 6, 2007
Recalling P446. P4501A1 (CYP1A1) opting for clinical applicationAlfred G Hildebrandt, Dieter Schwarz, Solveigh Krusekopf, et al.
Fundamental & Clinical Pharmacology|August 14, 2003
MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytesKersti Oselin, Thomas Gerloff, Przemyslaw M Mrozikiewicz, et al.
Pageof 10

Showing results (21-30 of 97) with videos related to

Sort By:
Pageof 10
Pharmacogenetics|October 3, 2002
Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteersJulia Kirchheiner, Ingolf Meineke, Gunnar Müller, et al.
Clinical Pharmacokinetics|December 24, 2005
Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevanceJulia Kirchheiner, Ivar Roots, Mark Goldammer, et al.
Personalized Medicine|May 26, 2018
The CYP2C9 polymorphism: from enzyme kinetics to clinical dose recommendationsJulia Kirchheiner, Martina Tsahuridu, Wafaa Jabrane, et al.
Pharmacogenetics|December 4, 2003
Trimipramine pharmacokinetics after intravenous and oral administration in carriers of CYP2D6 genotypes predicting poor, extensive and ultrahigh activityJulia Kirchheiner, Johanna Sasse, Ingolf Meineke, et al.
Clinical Chemistry|January 24, 2002
Rapid quantification of CYP3A4 expression in human leukocytes by real-time reverse transcription-PCRIsabella Nowakowski-Gashaw, Przemyslaw M Mrozikiewicz, Ivar Roots, et al.
Pharmacogenetics|October 3, 2002
Lack of association between arylamine N-acetyltransferase 2 (NAT2) polymorphism and systemic lupus erythematosusPetra Zschieschang, Falk Hiepe, Erika Gromnica-Ihle, et al.
Biochemical and Biophysical Research Communications|September 13, 2005
Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patternsDieter Schwarz, Pyotr Kisselev, Alexey Chernogolov, et al.
Analytical Biochemistry|October 7, 2004
Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probesFarhad Arjomand-Nahad, Konstanze Diefenbach, Olfert Landt, et al.
Drug Metabolism Reviews|September 6, 2007
Recalling P446. P4501A1 (CYP1A1) opting for clinical applicationAlfred G Hildebrandt, Dieter Schwarz, Solveigh Krusekopf, et al.
Fundamental & Clinical Pharmacology|August 14, 2003
MDR1 polymorphisms G2677T in exon 21 and C3435T in exon 26 fail to affect rhodamine 123 efflux in peripheral blood lymphocytesKersti Oselin, Thomas Gerloff, Przemyslaw M Mrozikiewicz, et al.
Pageof 10